Aeglea Biotherapeutics (AGLE) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Edward White maintained a Buy rating on Aeglea Biotherapeutics (AGLE) today and set a price target of $15.00. The company’s shares closed last Monday at $7.87.

According to, White is a top 100 analyst with an average return of 46.9% and a 50.3% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

Currently, the analyst consensus on Aeglea Biotherapeutics is a Strong Buy with an average price target of $14.00.

See today’s analyst top recommended stocks >>

Aeglea Biotherapeutics’ market cap is currently $381.4M and has a P/E ratio of -5.00. The company has a Price to Book ratio of 2.82.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts